Arca
Skip to content
Tools
Tools

Mucositis

Drug research and approvals for mucositis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 63 studies of mucositis are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.

  • Recruiting worldwide: 63
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 63 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

  • PaliferminFibroblast growth factor receptor 2 agonist

Phase 3 8

Phase 2 12

Phase 1 or earlier 4

How its trials ended

504 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 88 whose ending is known, 27% met their primary endpoint, 7% missed it and 66% stopped early.

  • Completed, result not reported23847%
  • Ongoing9920%
  • Status unknown7916%
  • Stopped: other or unclear326%
  • Met its primary endpoint245%
  • Stopped: enrollment or feasibility112%
  • Missed its primary endpoint61%
  • Stopped: funding61%
  • Stopped: sponsor or business decision51%
  • Stopped: lack of efficacy31%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Apr 7, 2025A single-centre, prospective, observational and proof-of-principle study of prevora's ability to treat peri-implant mucositis.ChlorhexidineCHX TechnologiesPending
Aug 8, 2018A phase 3, randomized, double-blind, placebo-controlled, multi-center study of the superoxide dismutase mimetic GC4419 to reduce severe oral mucositis (SOM)…Avasopasem (GC4419)Galera TherapeuticsOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 27, 2008Manganese superoxide dismutase mimeticPrevention of radiation- or chemotherapy-induced oral mucositis in cancer patientsGalera Therapeutics, LLCDesignated
Jan 29, 2004Recombinant human fibroblast growth factor-20Treatment of radiation induced oral mucositisCuraGen CorporationDesignated
May 18, 1998Benzydamine hydrochlorideProphylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.Angelini Pharmaceuticals, Inc.Designated
Jul 15, 1993SucralfateTreatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.Fuisz Technologies, Ltd.Designated
Aug 18, 1986Chlorhexidine gluconate mouthrinseFor use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow…Procter & Gamble CompanyDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.